-
Mashup Score: 12Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer - 5 month(s) ago
Circulating tumor DNA (ctDNA) has been used as a biomarker for prognostication and response to treatment. Here, we evaluate ctDNA as a potential biomarker for response to lorlatinib, a third-generation ALK tyrosine kinase inhibitor in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer (NSCLC) in the ongoing phase 3 CROWN study (NCT03052608).
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
A lymph node map is the pillar on which accurate assignment and documentation of nodal classification stands. The International Thymic Malignancy Interest Group created the first map for thymic epithelial malignancies in conjunction with the eighth edition of the TNM classification, representing the first official TNM classification of thymic epithelial malignancies. The map was based on clinical experience and published studies, but it was largely empirical because of limited available data. Dissemination of the map and implementation of a standard thymic stage classification across the world in 2017 have provided more consistent and granular data.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
This article details the process & considerations for refinement of the thymic map for the 9th edition of #TNM classification used by the Thymic Domain of the Staging & Prognostic Factors Committee of the #IASLC. https://t.co/fvzvduj01Y @sheba_medical @thoracicrad @Itmig_society https://t.co/vYvkTAmg0M
-
-
Mashup Score: 1317Lung Nodule Program Provides Benefits Patients Ineligible for Lung Cancer Screening | IASLC - 6 month(s) ago
Contact: Chris Martin, IASLC Media Relations | cmartin@davidjamesgroup.com (Denver – December 18, 2023) — Adopting a lung nodule program (LNP) may incre …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 24Lung Nodule Program Provides Benefits Patients Ineligible for Lung Cancer Screening | IASLC - 6 month(s) ago
Contact: Chris Martin, IASLC Media Relations | cmartin@davidjamesgroup.com (Denver – December 18, 2023) — Adopting a lung nodule program (LNP) may incre …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
A TNM-based system for all types of thymic epithelial tumors was introduced in the eighth edition of the TNM classification of thoracic malignancies. The Thymic Domain of the Staging and Prognostic Factors Committee of the International Association for the Study of Lung Cancer, composed of multispecialty international experts, was charged to develop proposals for the ninth edition. This article outlines the proposed definitions for the T, the N, and the M components and their combination into stage groups.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer - 6 month(s) ago
The role of a family history of lung cancer (LCFH) in screening using low-dose computed tomography (LDCT) has not been prospectively investigated with long-term follow-up.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
Though LCFH is often discussed, its use in LDCT had not been prospectively investigated w/long-term follow up until now. LCFH is a risk factor w/LC, & increases w/MF history among those who never smoked, younger adults, & those w/maternal relatives w/LC. https://t.co/HtC36lyJsI https://t.co/eOge6T72tG
-
-
Mashup Score: 24Brief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma - RIOMeso - 6 month(s) ago
Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-yr overall survival (OS) of 10%. First line immunotherapy with ipilimumab and nivolumab is now a standard of care for unresectable pleural mesothelioma following the CheckMate743 (CM743) trial, with supportive data from the later line single arm MAPS2 trial. RIOMeso examines survival and toxicity of this regimen in real-world practice.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
Australia has one of the highest rates of asbestos-associated diseases. RIOMeso is the 1st detailed report of real-world outcomes for ipilimumab/nivolumab for mesothelioma in Australia, revealing significant toxicity & less prominent survival benefit.https://t.co/xOYZ9ZWBPZ #LCSM https://t.co/6YKyHFTN4n
-
-
Mashup Score: 2
Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes compared with crizotinib in patients with previously untreated ALK-positive advanced NSCLC in the phase 3 CROWN study. Here, we investigated response correlates using plasma circulating tumor DNA (ctDNA) and tumor tissue profiling.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Clinical significance of IASLC proposed pathologic criteria for invasion in resected non-mucinous lung adenocarcinoma - 7 month(s) ago
Accurate diagnostic criteria for tumor invasion are essential for precise pathologic tumor (pT) staging. Recently, the IASLC Pathology Committee suggested a new criteria for assessing tumor invasion but clinical usefulness of the proposed criteria have not been evaluated.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Sequential anti–programmed cell death protein 1 (PD-1) or anti–programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC. KRASG12C inhibitor sotorasib may trigger severe immune-mediated hepatotoxicity when used in sequence or in combination with anti–PD-(L)1. This study was designed to address whether sequential anti–PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other AEs.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
Sequential anti-PD-1 or anti-PD-L1 followed by sotorasib use is associated w/increased prevalence of AEs in #NSCLC.Authors suggest avoiding starting sotorasib within 30 days from the last anti-PD-(L)1 infusion due to significant increased risk of toxicity. https://t.co/8BAWwhxcbh https://t.co/RFuavomBWp
-
Soo et al. evaluated #ctDNA as a potential biomarker for response to #lorlatinib. Their results suggest that ctDNA may be used to monitor and potentially predict the efficacy of lorlatinib treatment. Read more about their findings here! https://t.co/9X6VpP5seQ #LCSM https://t.co/nFmYOpABsV